FDAnews
www.fdanews.com/articles/82272-johnson-johnson-neutral-target-price-reduced

JOHNSON & JOHNSON 'NEUTRAL,' TARGET PRICE REDUCED

November 8, 2005

Analyst Glenn Novarro of Banc of America Securities maintains his "neutral" rating on Johnson & Johnson. The target price has been reduced from $72 to $65.
Newratings